Ligand Pharmaceuticals Incorporated

NasdaqGM:LGND Stock Report

Mkt Cap: US$1.2b

Ligand Pharmaceuticals Dividend

Dividend criteria checks 0/6

Ligand Pharmaceuticals Incorporated does not have a record of paying a dividend.

Key information

n/a

Dividend yield

n/a

Payout ratio

Industry average yield2.6%
Next dividend pay daten/a
Ex dividend daten/a
Dividend per shareUS$0
Earnings per share-US$1.26
Dividend yield forecast in 3Yn/a

Recent dividend updates

No updates

Recent updates

These 4 Measures Indicate That Ligand Pharmaceuticals (NASDAQ:LGND) Is Using Debt Reasonably Well

Jan 26
These 4 Measures Indicate That Ligand Pharmaceuticals (NASDAQ:LGND) Is Using Debt Reasonably Well

We Think Ligand Pharmaceuticals (NASDAQ:LGND) Can Stay On Top Of Its Debt

Oct 21
We Think Ligand Pharmaceuticals (NASDAQ:LGND) Can Stay On Top Of Its Debt

Ligand Pharmaceuticals: Struggling Along

Sep 25

Growth Investors: Industry Analysts Just Upgraded Their Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Revenue Forecasts By 11%

Aug 11
Growth Investors: Industry Analysts Just Upgraded Their Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Revenue Forecasts By 11%

Here's Why Ligand Pharmaceuticals (NASDAQ:LGND) Can Manage Its Debt Responsibly

Jun 27
Here's Why Ligand Pharmaceuticals (NASDAQ:LGND) Can Manage Its Debt Responsibly

Ligand Pharmaceuticals: Moving Parts Keep Moving

Mar 29

We Think Ligand Pharmaceuticals (NASDAQ:LGND) Can Manage Its Debt With Ease

Mar 17
We Think Ligand Pharmaceuticals (NASDAQ:LGND) Can Manage Its Debt With Ease

Ligand: Green Shoots And A Hidden Treasure - A Spinoff Bonus For The New Year

Dec 31

Is Ligand Pharmaceuticals (NASDAQ:LGND) A Risky Investment?

Dec 03
Is Ligand Pharmaceuticals (NASDAQ:LGND) A Risky Investment?

Is Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Trading At A 38% Discount?

Oct 11
Is Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Trading At A 38% Discount?

Ligand's Ailing Remdesivir Cash Cow

Oct 11

Is Ligand Pharmaceuticals (NASDAQ:LGND) A Risky Investment?

Aug 19
Is Ligand Pharmaceuticals (NASDAQ:LGND) A Risky Investment?

Ligand: 2021 Is Pivotal

Jul 16

Calculating The Fair Value Of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)

Jun 25
Calculating The Fair Value Of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)

Here's Why Shareholders May Want To Be Cautious With Increasing Ligand Pharmaceuticals Incorporated's (NASDAQ:LGND) CEO Pay Packet

May 29
Here's Why Shareholders May Want To Be Cautious With Increasing Ligand Pharmaceuticals Incorporated's (NASDAQ:LGND) CEO Pay Packet

Ligand Pharmaceuticals Incorporated Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

May 06
Ligand Pharmaceuticals Incorporated Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

Is Ligand Pharmaceuticals (NASDAQ:LGND) Using Too Much Debt?

May 03
Is Ligand Pharmaceuticals (NASDAQ:LGND) Using Too Much Debt?

Ligand Pharmaceuticals Q1 2021 Earnings Preview

May 02

Ligand, Lupin settle patent case over Evomela

Apr 27

Are Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Investors Paying Above The Intrinsic Value?

Mar 04
Are Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Investors Paying Above The Intrinsic Value?

Trade Alert: The Senior VP Of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND), Charles Berkman, Has Sold Some Shares Recently

Feb 06
Trade Alert: The Senior VP Of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND), Charles Berkman, Has Sold Some Shares Recently

Ligand and Travere announce promising data from late-stage sparsentan trial

Feb 02

One Of The Most Shorted Names In Biotech: Ligand Pharmaceuticals

Jan 30

Ligand receives milestone payment from Merck

Jan 13

Is Ligand Pharmaceuticals (NASDAQ:LGND) A Risky Investment?

Jan 13
Is Ligand Pharmaceuticals (NASDAQ:LGND) A Risky Investment?

Ligand Pharma's Icagen, GlaxoSmithKline in licensing pact for neurological diseases

Dec 21

How Should Investors React To Ligand Pharmaceuticals' (NASDAQ:LGND) CEO Pay?

Dec 18
How Should Investors React To Ligand Pharmaceuticals' (NASDAQ:LGND) CEO Pay?

Stability and Growth of Payments

How stable has Ligand Pharmaceuticals's dividend per share been in the past?
MonthDividend Per Share (annual)Avg. Yield (%)

Stable Dividend: Insufficient data to determine if LGND's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if LGND's dividend payments have been increasing.


Dividend Yield vs Market

Ligand Pharmaceuticals Dividend Yield vs Market
How does LGND dividend yield compare to the market?
SegmentDividend Yield
Company (LGND)n/a
Market Bottom 25% (US)1.5%
Market Top 25% (US)4.2%
Industry Average (Pharmaceuticals)2.6%
Analyst forecast in 3 Years (LGND)n/a

Notable Dividend: Unable to evaluate LGND's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate LGND's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as LGND has not reported any payouts.


Discover strong dividend paying companies